Rare variants in genes associated with idiopathic hypogonadotropic hypogonadism are found in some women with functional hypothalamic amenorrhea, according to research published in the Jan. 20 issue of the New England Journal of Medicine.
THURSDAY, Jan. 20 (HealthDay News) -- Rare variants in genes associated with idiopathic hypogonadotropic hypogonadism are found in some women with functional hypothalamic amenorrhea, according to research published in the Jan. 20 issue of the New England Journal of Medicine.
Lisa M. Caronia, of the Massachusetts General Hospital in Boston, and colleagues investigated whether women's varying susceptibility to inhibition of the reproductive axis has a genetic predisposition. They analyzed the coding sequence of genes associated with idiopathic hypogonadotropic hypogonadism in 55 women with hypothalamic amenorrhea and 422 control women with normal menstrual cycles.
The researchers found six heterozygous mutations in seven of the women with hypothalamic amenorrhea. The affected genes, which play fundamental roles in gonadotropin-releasing hormone ontogeny and function, were found to have loss-of-function mutations. Several of the identified mutations had previously been associated with idiopathic hypogonadotropic hypogonadism. No mutations were identified in the control group. The researchers observed evidence of the role of rare variants in common multifactorial disease.
"We speculate that such heterozygous mutations, while not sufficient to cause idiopathic hypogonadotropic hypogonadism, could set a lower threshold for functional inhibition of the hypothalamic-pituitary-gonadal axis under adverse hormonal, nutritional, or psychological conditions and thereby lead to hypothalamic amenorrhea," the authors write.
One author disclosed financial relationships with Humana and Ferring Pharmaceuticals; another author disclosed a previous financial relationship with Novartis.
Full Text (subscription or payment may be required)
Related ContentEducational Tutorial: Secondary AmenorrheaAssessment of a Case of Amenorrhea
Daré Bioscience initiates phase 3 clinical trial for ovaprene contraceptive
December 5th 2023Daré Bioscience has commenced a pivotal phase 3 clinical trial for ovaprene, an intravaginal contraceptive that releases a locally acting agent to prevent sperm entry into the cervical canal, marking a significant step towards a non-hormonal contraceptive option for women.
Read More
Exploring menstrual health: Insights from the Avon longitudinal study
December 5th 2023Unveiling a comprehensive analysis of menstrual cycle characteristics in mothers and daughters, this article delves into the diverse features, potential risk factors, and the importance of understanding these nuances for effective menstrual health management.
Read More
Integrating pharmacists into PPHTN management for enhanced blood pressure control
December 4th 2023A study reveals that involving pharmacists in the care of postpartum women at risk of persistently elevated blood pressure, as presented at the American Society of Health-System Pharmacists 2023 Midyear Clinical Meeting and Exhibition, can provide an effective and feasible solution to managing hypertensive disorders, reducing postpartum readmission risks, and improving overall health care access.
Read More